A network meta-analysis comparing anti-VEGF agents, dosing and injection frequency for the treatment of neovascular age-related macular degeneration found comparable outcomes for all included anti-VEGF regimens, according to a presenter at the virtual Association for Research in Vision and Ophthalmology meeting.
“These data suggest that no single anti-VEGF regimen is associated with superior vision outcomes for patients with nAMD and that achieving further vision gains may require a different approach to treatment, such as a different drug delivery paradigm or drugs with an alternative
Uncategorized